{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:07:09Z","timestamp":1785521229059,"version":"3.56.0"},"reference-count":22,"publisher":"Baskent University","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.6002\/ect.2026.0114","type":"journal-issue","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T09:21:14Z","timestamp":1782897674000},"source":"Crossref","is-referenced-by-count":1,"title":[],"prefix":"10.6002","volume":"24","member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Afzal MR, Evanson C, Cardona A, Rusk K, Weiss R. Arrhythmogenic right ventricular cardiomyopathy. In: Vasan RS, Sawyer DB, eds. Encyclopedia of Cardiovascular Research and Medicine. Elsevier; 2018:182-191.","DOI":"10.1016\/B978-0-12-809657-4.10912-3"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Lund LH, Edwards LB, Dipchand AI, et al.; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; focus theme: primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35(10):1158-1169. doi:10.1016\/j.healun.2016.08.017","DOI":"10.1016\/j.healun.2016.08.017"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Fuchs M, Schibilsky D, Zeh W, Berchtold-Herz M, Beyersdorf F, Siepe M. Does the heart transplant have a future? Eur J Cardiothorac Surg. 2019;55(Suppl 1):i38- i48. doi:10.1093\/ejcts\/ezz107","DOI":"10.1093\/ejcts\/ezz107"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018;18(2):293-307. doi:10.1111\/ajt.14625.","DOI":"10.1111\/ajt.14625"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Panicker AJ, Prokop LJ, Hacke K, Jaramillo A, Griffiths LG. Outcome-based risk assessment of non-HLA antibodies in heart transplantation: a systematic review. J Heart Lung Transplant. 2024;43(9):1450-1467. doi:10.1016\/j.healun.2024.05.012","DOI":"10.1016\/j.healun.2024.05.012"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Hurskainen M, Ainasoja O, Lemstr\u00f6m KB. Failing heart transplants and rejection: a cellular perspective. J Cardiovasc Dev Dis. 2021;8(12):180. doi:10.3390\/jcdd8120180","DOI":"10.3390\/jcdd8120180"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Smith JD, Banner NR, Hamour IM, et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant. 2011;11(2):312-319. doi:10.1111\/j.1600-6143.2010.03383.x","DOI":"10.1111\/j.1600-6143.2010.03383.x"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation. 2002;74(8):1192-1194. doi:10.1097\/00007890-200210270-00025","DOI":"10.1097\/00007890-200210270-00025"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Colvin MM, Cook JL, Chang P, et al; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiopulmonary Critical Care, Perioperative and Resuscitation; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Disease in the Young; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Radiology and Intervention; American Heart Association Heart Failure and Transplantation Committee of the Council on Cardiovascular Surgery and Anesthesia. Antibody-mediated rejection in cardiac transplantation: Emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2015;131(18):1608-1639. doi:10.1161\/CIR.0000000000000093","DOI":"10.1161\/CIR.0000000000000093"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Loupy A, Cazes A, Guillemain R, et al. Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy. Am J Transplant. 2011;11(7):1478-1487. doi:10.1111\/j.1600-6143.2011.03563.x","DOI":"10.1111\/j.1600-6143.2011.03563.x"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Kfoury AG, Hammond ME, Snow GL, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J Heart Lung Transplant. 2009;28(8):781-784. doi:10.1016\/j.healun.2009.04.035","DOI":"10.1016\/j.healun.2009.04.035"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Peng B, Zhuang Q, Yu M, et al. Comparison of physical crossmatch and virtual crossmatch to identify preexisting donor-specific human leukocyte antigen (HLA) antibodies and outcome following kidney transplantation. Med Sci Monit. 2019;25:952-961. doi:10.12659\/MSM.914902","DOI":"10.12659\/MSM.914902"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Navr\u00e1tilov\u00e1 A, Be\u010dv\u00e1\u0159 V, Hulejov\u00e1 H, et al. New pro-inflammatory cytokine IL-40 is produced by activated neutrophils and plays a role in the early stages of seropositive rheumatoid arthritis. RMD Open. 2023;9(2):e002894. doi:10.1136\/rmdopen-2022-002894","DOI":"10.1136\/rmdopen-2022-002894"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Guggino G, Rizzo C, Mohammadnezhad L, et al. Possible role for IL-40 and IL-40-producing cells in the lymphocytic infiltrated salivary glands of patients with primary Sj\u00f6gren's syndrome. RMD Open. 2023;9(2):e002738. doi:10.1136\/rmdopen-2022-002738","DOI":"10.1136\/rmdopen-2022-002738"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Yu S, Su C, Luo X. Impact of infection on transplantation tolerance. Immunol Rev. 2019;292(1):243-263. doi:10.1111\/imr.12803","DOI":"10.1111\/imr.12803"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Kov\u00e1cs KG, M\u00e1csik-Valent B, Matk\u00f3 J, Bajtay Z, Erdei A. Revisiting the coreceptor function of complement receptor type 2 (CR2, CD21); coengagement with the B-cell receptor inhibits the activation, proliferation, and antibody production of human B cells. Front Immunol. 2021;12:620427. doi:10.3389\/fimmu.2021.620427","DOI":"10.3389\/fimmu.2021.620427"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Nait Mohamed FA, Lingwood D. Innate immunity and training to subvert original antigenic sin by the humoral immune response. Elife. 2025;14:e106654. doi:10.7554\/eLife.106654","DOI":"10.7554\/eLife.106654"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Wentink MW, Lambeck AJ, van Zelm MC, et al. CD21 and CD19 deficiency: two defects in the same complex leading to different disease modalities. Clin Immunol. 2015;161(2):120-127. doi:10.1016\/j.clim.2015.08.010","DOI":"10.1016\/j.clim.2015.08.010"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Nijland M, Veenstra RN, Visser L, et al. HLA dependent immune escape mechanisms in B-cell lymphomas: implications for immune checkpoint inhibitor therapy? Oncoimmunology. 2017;6(4):e1295202. doi:10.1080\/2162402X.2017.1295202","DOI":"10.1080\/2162402X.2017.1295202"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Fei F, Rong L, Jiang N, Wayne AS, Xie J. Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor. Mol Ther. 2022;30(3):1215-1226. doi:10.1016\/j.ymthe.2021.11.013","DOI":"10.1016\/j.ymthe.2021.11.013"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Rimmel\u00e9 T, Payen D, Cantaluppi V, et al; ADQI XIV Workgroup. Immune cell phenotype and function in sepsis. Shock. 2016;45(3):282-291. doi:10.1097\/SHK.0000000000000495","DOI":"10.1097\/SHK.0000000000000495"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Cai S, Li X, Zhang C, Jiang Y, et al. Inhibition of Interleukin-40 prevents multi-organ damage during sepsis by blocking NETosis. Crit Care. 2025;29(1):29. doi:10.1186\/s13054-025-05257-2","DOI":"10.1186\/s13054-025-05257-2"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T09:35:20Z","timestamp":1782898520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ectrx.org\/detail\/archive\/2026\/24\/5\/0\/411\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2026.0114","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}